CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2006--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three- and six-month periods ended December 31, 2005 - the second quarter and first half, respectively, of the Company's 2006 fiscal year.
